(MEnD-AKI) Multicenter Implementation of an Electronic Decision Support System for Drug-associated AKI
(MEnD-AKI) 药物相关 AKI 电子决策支持系统的多中心实施
基本信息
- 批准号:10609525
- 负责人:
- 金额:$ 63.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:Acute Renal Failure with Renal Papillary NecrosisAddressAdoptedAdultAdverse drug eventCaringCessation of lifeChronicClinicalClinical Decision Support SystemsClinical Practice GuidelineComputerized Medical RecordCost AnalysisCoupledDataDecision Support SystemsDependenceDevelopmentDiagnosticDialysis procedureDoseDrug ModelingsEarly DiagnosisEffectivenessElectronicsEquipmentEtiologyEventGoalsGuidelinesHealth systemHospitalistsHospitalizationHospitalsIncidenceInjury to KidneyInstitutionInterventionKidney DiseasesLaboratoriesLength of StayLightMachine LearningMeasuresMedical centerOperative Surgical ProceduresOutcomePatient CarePatient-Focused OutcomesPatientsPerceptionPerformancePharmaceutical PreparationsPharmacistsPhysiciansPredictive AnalyticsPredictive ValueProviderPublishingRandomizedRandomized, Controlled TrialsRecommendationRecoveryReportingResearchResidual stateRiskRisk AssessmentSeriesServicesSiteSpecificityStagingSurveysSystemTestingTherapeutic InterventionTimeTrainingUnited StatesUniversitiesUpdateaging populationcare providersclinical decision supportclinical riskcomorbiditycostcost effectivenessdesigndetection platformeffectiveness evaluationexperiencegroup interventionhigh riskimaging agentimplementation costimplementation interventionimprovedinnovationmortalitynephrotoxicitynon-drugpost interventionprematurerenal damagerisk prediction modelstandard of care
项目摘要
Abstract
Acute Kidney Injury (AKI) in the US has increased by 38% over the last eight years, with drugs as a major
contributor to AKI in hospitalized patients. Drug-associated AKI (D-AKI) results in severe consequences with
approximately 40% of patients experiencing in-hospital death or dialysis dependence and 70% having
evidence of residual kidney damage following the initial D-AKI event. We have determined that many patients
at high risk for AKI are identified late and often continue to receive nephrotoxic drugs until AKI becomes
severe. Thus, we designed a proposal to address the need for early, appropriate management of nephrotoxins
in high-risk patients by studying the effect of an advanced clinical decision support system (CDSS) for primary
physicians and hospitalists aimed at reducing D-AKI in hospitalized adults. Specifically, we aim to 1) optimize
the clinical performance of D-AKI risk-alerts generated by a clinical decision support system; 2) test whether an
advanced clinical decision support system coupled with a pharmacist-led intervention improves short and long-
term outcomes for patients with D-AKI; and 3) determine physician perception of the pharmacists’
performance, physician acceptance and cost-effectiveness of our intervention.
In 2012 Kidney Disease Improving Global Outcomes (KDIGO) published the first comprehensive AKI clinical
practice guideline. Recommendations include the use of standard criteria for defining and staging AKI and a
series of stage-based management steps to be considered for all patients with AKI or at risk for developing it.
However, clinicians have been slow to adopt these recommendations and some groups (most notably the US
KDOQI expert panel), while endorsing the guideline overall, have called for more research testing the
recommendations. Our proposal directly addresses this concern by testing whether a unique clinical decision
support system identifying high risk patients coupled with an advanced pharmacist service directed to the
primary physician can address D-AKI and drug dosing for other forms of AKI to improve patient care. Thus, our
central goal is to examine the effect of a pharmacist-led intervention on the early detection and management of
AKI, progression of and short-term recovery from AKI, and on various AKI-related outcomes.
摘要
在过去的八年里,美国的急性肾损伤(阿基)增加了38%,其中药物是主要原因。
住院患者中阿基的贡献者。药物相关阿基(D-AKI)导致严重后果,
大约40%的患者经历院内死亡或透析依赖,70%的患者
初始D-AKI事件后残留肾损伤的证据。我们发现很多病人
AKI高风险患者被发现较晚,并且经常继续接受肾毒性药物,直到阿基成为
严重。因此,我们设计了一个建议,以解决需要早期,适当的管理肾毒素
通过研究高级临床决策支持系统(CDSS)对原发性肝癌的影响,
旨在减少住院成人中的D-AKI。具体而言,我们的目标是:1)优化
由临床决策支持系统生成的D-AKI风险警报的临床性能; 2)测试
先进的临床决策支持系统加上药剂师主导的干预改善了短期和长期的,
D-AKI患者的长期结局;以及3)确定医生对药剂师
性能、医生接受度和我们干预的成本效益。
2012年,改善肾脏疾病全球结局(KDIGO)发表了第一份全面的阿基临床研究报告。
实践指南。建议包括使用标准标准来定义和分期阿基,
所有AKI患者或有发生AKI风险的患者应考虑一系列基于阶段的管理步骤。
然而,临床医生在采纳这些建议方面进展缓慢,一些团体(尤其是美国)
KDOQI专家小组),虽然总体上支持该指南,但呼吁进行更多的研究测试,
建议.我们的建议通过测试一个独特的临床决策是否
识别高风险患者的支持系统,再加上针对
主治医生可以解决D-AKI和其他形式的阿基的药物给药,以改善患者护理。所以我们
中心目标是检查药剂师领导的干预对早期发现和管理的影响。
阿基、阿基进展和短期恢复,以及各种AKI相关结局。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Azra Bihorac其他文献
Azra Bihorac的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Azra Bihorac', 18)}}的其他基金
Bridge2AI: Patient-Focused Collaborative Hospital Repository Uniting Standards (CHoRUS) for Equitable AI
Bridge2AI:以患者为中心的协作医院存储库统一标准 (CHORUS),实现公平的人工智能
- 批准号:
10858694 - 财政年份:2022
- 资助金额:
$ 63.56万 - 项目类别:
Bridge2AI: Patient-Focused Collaborative Hospital Repository Uniting Standards (CHoRUS) for Equitable AI
Bridge2AI:以患者为中心的协作医院存储库统一标准 (CHORUS),实现公平的人工智能
- 批准号:
10472824 - 财政年份:2022
- 资助金额:
$ 63.56万 - 项目类别:
(MEnD-AKI) Multicenter Implementation of an Electronic Decision Support System for Drug-associated AKI
(MEnD-AKI) 药物相关 AKI 电子决策支持系统的多中心实施
- 批准号:
10414976 - 财政年份:2021
- 资助金额:
$ 63.56万 - 项目类别:
(MEnD-AKI) Multicenter Implementation of an Electronic Decision Support System for Drug-associated AKI
(MEnD-AKI) 药物相关 AKI 电子决策支持系统的多中心实施
- 批准号:
10594086 - 财政年份:2021
- 资助金额:
$ 63.56万 - 项目类别:
ADAPT: Autonomous Delirium Monitoring and Adaptive Prevention
ADAPT:自主谵妄监测和适应性预防
- 批准号:
10396041 - 财政年份:2021
- 资助金额:
$ 63.56万 - 项目类别:
ADAPT: Autonomous Delirium Monitoring and Adaptive Prevention
ADAPT:自主谵妄监测和适应性预防
- 批准号:
10178157 - 财政年份:2021
- 资助金额:
$ 63.56万 - 项目类别:
Intelligent Intensive Care Unit (I2CU): Pervasive Sensing and Artificial Intelligence for Augmented Clinical Decision-making
智能重症监护病房 (I2CU):普遍传感和人工智能增强临床决策
- 批准号:
10154047 - 财政年份:2021
- 资助金额:
$ 63.56万 - 项目类别:
(MEnD-AKI) Multicenter Implementation of an Electronic Decision Support System for Drug-associated AKI
(MEnD-AKI) 药物相关 AKI 电子决策支持系统的多中心实施
- 批准号:
10209005 - 财政年份:2021
- 资助金额:
$ 63.56万 - 项目类别:
Intelligent Intensive Care Unit (I2CU): Pervasive Sensing and Artificial Intelligence for Augmented Clinical Decision-making
智能重症监护病房 (I2CU):普遍传感和人工智能增强临床决策
- 批准号:
10580785 - 财政年份:2021
- 资助金额:
$ 63.56万 - 项目类别:
Intelligent Intensive Care Unit (I2CU): Pervasive Sensing and Artificial Intelligence for Augmented Clinical Decision-making
智能重症监护病房 (I2CU):普遍传感和人工智能增强临床决策
- 批准号:
10374834 - 财政年份:2021
- 资助金额:
$ 63.56万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 63.56万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 63.56万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 63.56万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 63.56万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 63.56万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 63.56万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 63.56万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 63.56万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 63.56万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 63.56万 - 项目类别:
Research Grant














{{item.name}}会员




